Researchers at UT Southwestern Medical Center have discovered how a hormone interacts with a receptor on the surface of immune cells to shield cancer cells from the body’s natural defenses.
FDA July 23 extended the review period for the Biologics License Application for Blenrep (belantamab mafodotin-blmf) combinations for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
FDA issued a Complete Response Letter regarding the Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
FDA granted Breakthrough Therapy designation to elironrasib, a RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.
The European Commission has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic and extra-pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
European Medicines Agency has granted Orphan Drug designation to ICT01, a humanized anti-butyrophilin 3A monoclonal antibody designed to selectively activate γ9δ2 T cells, for the treatment of acute myeloid leukemia. AML has high unmet medical need and limited treatment options for older or unfit patients who are not eligible for intensive chemotherapy.
The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.
NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.
President Trump said he would impose tariffs on pharmaceutical products and semiconductors as soon as Aug. 1.
The Centers for Medicare & Medicaid Services published a proposed rule, which it says aligns with Trump’s “Big Beautiful Bill.”
